Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Expeditors International of Wshngtn Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.41 (market cap $5.07B), while Expeditors International of Wshngtn Inc trades at $179.93 (market cap $23.04B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 4.5× ACADIA Pharmaceuticals Inc.'s market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EXPD | |
|---|---|---|
Market Cap | $5.07B | $23.04B |
Sector | Health | Industrials |
52-Week High | $29.41 | $182.80 |
52-Week Low | $20.06 | $113.13 |
Enterprise Value | $4.19B | $22.57B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
EXPD trades at $179.00, near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $2.03 per share, beating estimates by 20%, driven by airfreight and customs demand. Revenue growth is steady, with 2026 projected at $12.0B, though ocean freight contraction poses a headwind. Analyst consensus is a Hold with a $181.14 price target, indicating limited near-term upside.
Outlook: EXPD's earnings momentum and expanding AOG services offer growth potential, but high valuation (P/E 25.79) and reliance on tariff policies heighten risk. Investors should weigh robust profitability (ROE 42.6%) against cyclical freight pressures and analyst caution. The stock is fairly valued, with gains contingent on sustaining airfreight strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
